Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. by Pender, Alexandra et al.
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung
Cancer Using a Multiplexed Droplet Digital PCR Approach.
Pender, A., Garcia-Murillas, I., Rana, S., Cutts, R. J., Kelly, G., Fenwick, K., ... Downward, J. (2015). Efficient
Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
PLoS One, 10(9). DOI: 10.1371/journal.pone.0139074
Published in:
PLoS One
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2015 Pender et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
RESEARCH ARTICLE
Efficient Genotyping of KRASMutant Non-
Small Cell Lung Cancer Using a Multiplexed
Droplet Digital PCR Approach
Alexandra Pender1,2,3, Isaac Garcia-Murillas4, Sareena Rana1, Rosalind J. Cutts4,
Gavin Kelly3, Kerry Fenwick4, Iwanka Kozarewa4, David Gonzalez de Castro5,
Jaishree Bhosle2, Mary O’Brien2, Nicholas C. Turner2,4, Sanjay Popat2,
Julian Downward1,3*
1 Lung Cancer Group, Division of Molecular Pathology, The Institute of Cancer Research, London, United
Kingdom, 2 Department of Medicine, The Royal Marsden NHS Foundation Trust, London, United Kingdom,
3 The Francis Crick Institute, London, United Kingdom, 4 The Breakthrough Breast Cancer Research
Centre, The Institute of Cancer Research, London, United Kingdom, 5 The Centre for Molecular Pathology,
The Institute of Cancer Research, Sutton, United Kingdom
* julian.downward@crick.ac.uk
Abstract
Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-
driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a
multiplex approach to efficient mutation detection in circulating DNA. Here we report the
design and optimisation of three discriminatory ddPCRmultiplex assays investigating nine
different KRASmutations using PrimePCR™ ddPCR™Mutation Assays and the Bio-Rad
QX100 system. Together these mutations account for 95% of the nucleotide changes found
in KRAS in human cancer. Multiplex reactions were optimised on genomic DNA extracted
from KRASmutant cell lines and tested on DNA extracted from fixed tumour tissue from a
cohort of lung cancer patients without prior knowledge of the specific KRAS genotype. The
multiplex ddPCR assays had a limit of detection of better than 1 mutant KRASmolecule in
2,000 wild-type KRASmolecules, which compared favourably with a limit of detection of 1 in
50 for next generation sequencing and 1 in 10 for Sanger sequencing. Multiplex ddPCR
assays thus provide a highly efficient methodology to identify KRASmutations in lung
adenocarcinoma.
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide [1] and over 20 000
cases of non-small cell lung cancer (NSCLC) were diagnosed in the UK in 2012 [2]. The most
frequently mutated oncogenes in lung adenocarcinoma are the RAS family GTPases and EGFR
(25% and 15% respectively [3]). Knowledge of the molecular profile of advanced lung adeno-
carcinoma is critical for therapeutic decision-making [4], particularly in the use of EGFR and
ALK tyrosine kinase inhibitors [5,6]. The presence of a KRASmutation may also be of
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therapeutic relevance if MEK inhibitor and taxane combinations prove efficacious in this
patient cohort [7]. Obtaining adequate tumour tissue for conclusive genotyping in lung cancer
can be problematic, however [8]. Droplet digital PCR (ddPCR) is a sensitive method of quanti-
tative mutation detection [9,10] that has the potential to accurately genotype patient-derived
material from a small amount of starting material.
Detection of KRAS hotspot mutations by ddPCR has been limited by the variety of potential
alleles within adjacent loci, although some KRASmutations occur more commonly in cancer
than others (Tables 1 and 2). The four commonest mutations account for 80% of all KRAS
nucleotide changes found in human cancers (85% of all changes in NSCLC), while the nine com-
monest mutations account for 95% of all changes and 97.5% of changes in NSCLC. Fluorophore
—labelled digital PCR probes complement a particular mutant DNA sequence and so only detect
one specificKRASmutation. Using these assays in duplex with a probe to detect the mutant allele
and a probe to detect the wild-type allele allow mutant allele fraction calculation for a given
mutation, but this approach requires potentially multiple assays and the use of more material
before correct identification of the genotype. Development of a multiplex assay combining sev-
eral different mutant probes in the same reaction is therefore an attractive alternative. Multiplex
KRAS digital PCR assays have been described using the RainDrop™Digital PCR system (Rain-
Dance Technologies, Billerica, Massachusetts, USA) in advanced colorectal cancer [11] but not
as yet with the Bio-Rad QX100 system, an affordable digital PCR system with commercially-
available probes for several KRASmutations, nor has a multiplex tool been used in lung cancer.
We set out to design multiplex digital PCR assays which would accurately identify nine dif-
ferent KRASmutations and to demonstrate the application of these assays to patient-derived
material using the Bio-Rad QX100 system.
Materials and Methods
Digital PCR probe assays
Each digital PCR probe is an oligonucleotide specific to the region of interest with a 5’ fluoro-
phore and a 3’ quencher. The fluorophore is either HEX for probes specific to wild-type
sequences or FAM for mutant probes. KRAS c.35G>T (G12V; cat no. dHsaCP2500592),
c.35G>A (G12D; cat no. dHsaCP2500596), c.35G>C (G12A; cat no. dHsaCP2500586),
c.34G>A (G12S; cat no. dHsaCP2500588), c.34G>C (G12R; cat no. dHsaCP2500590),
c.34G>T (G12C; dHsaCP2500584), c.37G>T (G13C; cat no. dHsaCP2500595), c.38G>A
(G13D; cat no. dHsaCP2500598), c.183A>C (Q61H; cat no. dHsaCP2000133), WT for
c.35G>T (WT for G12V; cat no. dHsaCP2500593), WT for c.35G>A (WT for G12D; cat no.
Table 1. KRASmutations observed in human cancer in order of decreasing frequency (http://www.
sanger.co.uk/cosmic; accessed 14th July 2015).
KRAS genotype Mutation Cases Frequency
G12D c.35G>A 10719 33.8%
G12V c.35G>T 7138 22.5%
G13D c.38G>A 3959 12.5%
G12C c.34G>T 3713 11.7%
G12A c.35G>C 1694 5.3%
G12S c.34G>A 1507 4.7%
G12R c.34G>C 1024 3.2%
G13C c.37G>T 276 0.9%
Q61H c.183A>C 144 0.5%
doi:10.1371/journal.pone.0139074.t001
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dHsaCP2000002), WT for c.35G>C (WT for G12A; cat no. dHsaCP2000004), WT for
c.34G>A (WT for G12S; cat no. dHsaCP2000012), WT for c.34G>C (WT for G12R; cat no.
dHsaCP2000010), WT for c.34G>T (WT for G12C; cat no. dHsaCP2000008), WT for
c.37G>T (WT for G13C; cat no. dHsaCP2500595), WT for c.38G>A (WT for G13D; cat no.
dHsaCP2000014) and WT for c.183A>C (WT for Q61H; cat no. dHsaCP2000132) 20x Pri-
mePCR™ ddPCR™Mutation Assays (containing both primers and ddPCR probes) were pur-
chased from Bio-Rad (Bio-Rad Laboratories, Hercules, California, USA) and used in this study.
Assay optimisation and DNA quantification
Digital PCR assays were optimised using cell line genomic DNA (gDNA) or synthetic oligonu-
cleotides as appropriate. Cell lines used for this study were authenticated using STR profiling
by the Cell Services facility at the Cancer Research UK London Research Institute and the Insti-
tute of Cancer Research. These included NCI-H727 (KRAS G12V, lung), NCI-H358 (KRAS
G12C, lung), A549 (KRAS G12S, lung), SK-LU-1 (KRAS G12D, lung), A427 (KRAS G12D,
lung), HCT-116 (KRAS G13D, colon) and NCI-H1975 (KRASWT, lung). All cell lines were
provided directly by Cancer Research UK Cell Services with the exception of HCT-116 (Ameri-
can Type Culture Collection, Rockville, Maryland, USA; cat. no ATCC
1
CCL-247TM). Cell
gDNA was extracted using the DNeasy™ Blood and Tissue Kit (Qiagen, Venlo, Limburg, Neth-
erlands) as per manufacturer’s instructions. All DNA used in subsequent digital PCR reactions,
except synthetic oligonucleotides, was quantified on a QX100 ddPCR system using human
RNase P TaqMan1 Copy Number Reference Assay (Life Technologies Corporation, Carlsbad,
California, USA). 1 μL of eluate was added to a digital PCR reaction containing 10 μL ddPCR
Supermix for probes (Bio-Rad) and 1 μL of TaqMan Copy Number Reference Assay, human,
RNase P (Life Technologies) on a total volume of 20 μL. The reaction was partitioned into
~14,000 droplets per sample in a QX-100 droplet generator according to manufacturer’s
instructions. Emulsified PCR reactions were run on a 96 well plate (Eppendorf, Stevenage, UK)
on a G-Storm GS4 thermal cycler (G-Storm, Somerton, Somerset, UK) incubating the plates at
95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec, followed by 10
min incubation at 98°C. The temperature ramp increment was 2.5°C/sec for all steps. Plates
were read on a Bio-Rad QX-100 droplet reader using QuantaSoft v1.4.0.99 software (Bio-Rad).
At least one negative control wells with no DNA were included in every run. The amount of
amplifiable RNase P DNA was quantified from the concentration provided by the software.
After quantification, cell line DNA was digested using Hind 3-HF™ restriction enzyme (New
England BioLabs, Ipswich, Massachusetts, USA) at 37°C for 1 hour.
Table 2. KRASmutations observed in human NSCLC in order of decreasing frequency (http://www.
sanger.co.uk/cosmic; accessed 14th July 2015).
KRAS genotype Mutation Cases Frequency
G12C c.34G>T 604 36.7%
G12V c.35G>T 350 21.3%
G12D c.35G>A 336 20.4%
G12A c.35G>C 107 6.5%
G13C c.37G>T 54 3.3%
G12S c.34G>A 53 3.2%
G13D c.38G>A 43 2.6%
G12R c.34G>C 36 2.2%
Q61H c.183A>C 20 1.2%
doi:10.1371/journal.pone.0139074.t002
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Droplet digital PCR for KRASmutation detection
PCR reaction mixtures were prepared in a total volume of 20 μL containing: 10 μL 2x Supermix
for Probes without dUTP (Bio-Rad), relevant primer probe assays, DNA (variable volume) and
nuclease-free water (Life Technologies Corporation, Carlsbad, California, USA). Multiple wells
were used if required to analyse the necessary DNA eluate. At least 500 pg equivalent of DNA
eluate was analysed in each multiplex assay for each patient. 20 μL of PCR reaction mixture
was transferred to a sample well in a disposable droplet generator cassette (Bio-Rad). 70 μL of
droplet generation oil (Bio-Rad) was then loaded into the oil well for each channel and the cas-
sette loaded into a QX100 Droplet Generator (Bio-Rad). The droplets were then transferred to
a 96-well PCR plate. Emulsified PCR reactions were run on a G-Storm GS4 thermal cycler
incubating the plates at 95°C for 10 min followed by 40 cycles of 94°C for 30 sec and 54°C for
60 sec, followed by 10 min incubation at 98°C. The temperature ramp increment was 2.5°C/sec
for all steps. Plates were read on a Bio-Rad QX-100 droplet reader using QuantaSoft v1.4.0.99
software from Bio-Rad. At least one negative control well with no DNA was included in every
run. Each well was then read using the QX100 Droplet Reader (Bio-Rad) and droplets analysed
for emission in the HEX or FAM wavelengths. Two-dimensional amplitude plots displaying
measured HEX and FAM amplitude for each droplet show four main droplet populations;
droplets containing no amplified DNA, droplets with only mutant DNA and high FAM ampli-
tude, droplets with only wild-type DNA and high HEX amplitude and droplets with both wild-
type and mutant amplified DNA and high FAM and HEX amplitude. If multiple copies of
wild-type and mutant DNA are contained in the same droplet, droplets with higher FAM and
HEX amplitude will be read. These droplets have been excluded from any analyses throughout
this study.
Digital PCR analysis
To assess the mutant allele fraction, the concentration of mutant DNA (copies of mutant DNA
per droplet) was estimated from the Poisson distribution. Number of mutant copies per droplet
Mmu = -ln (1-(nmu/n)), where nmu = number of droplets positive for mutant FAM probe and
n = total number of droplets. The DNA concentration in the reaction was estimated as follows:
MDNAconc = -ln (1-(nDNAcon/n)), where nDNAconc = number of droplets positive for
mutant FAM probe and/or wild-type HEX probe and n = total number of droplets. The mutant
allele fraction = Mmu/ MDNAconc. The measured mutant allele frequency describes the
mutant allele fraction expressed as a percentage.
FFPE tissue DNA access and extraction
Formalin fixed paraffin embedded (FFPE) tumour samples from NSCLC patients surplus to
clinical care were collected with written patient consent at The Royal Marsden NHS Founda-
tion Trust. FFPE tissue DNA was extracted (after macrodissection if required to ensure>10%
tumour content) using the Qiagen DNA FFPE Tissue Kit (Qiagen) as per manufacturer’s
instructions. The eluted DNA was stored at -20°C.
Ethics statement
All patients provided written consent to this study (ethics approval 13/LO/1389, NRES Com-
mittee London-Central), which incorporated surplus somatic DNA from the Cancer Research
UK Stratified Medicine Programme (ethics approval 11/EE/0202, NRES Committee East of
England).
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Sanger sequencing
The region of interest was amplified using 10 μM forward (5’-TATTATAAGGCCTGCTGA
AAATG-3’) and reverse (5’-TTGGATCATATTCGTCCACAA-3’) primers, 10 μL Amplitaq
Gold1 PCRMaster Mix (Life Technologies) and 3 ng of template FFPE—derived DNA or 5ng
gDNA. PCR conditions were as per manufacturer’s recommendations. Purified PCR product
then underwent a further PCR step using chain-terminating dideoxynucleotides (BigDye1 1.0,
Life Technologies) and subsequent DNA sequence was read on an automated sequencer.
Ion torrent proton sequencing
Sequencing libraries were prepared with the Ion AmpliSeq™ Cancer Hotspot Panel v2 (Life
Technologies) using the Ion AmpliSeq Library Preparation protocol with 3-5ng of DNA,
according to manufacturer’s instructions. Following barcoding, libraries were quantified using
qPCR and diluted to 100 pM. Libraries were templated with the Ion OneTouch2 system (Life
Technologies) and sequenced on a PI chip using the Ion PI OT2 200 Kit (Life Technologies),
520 flows and an average amplicon length of 112 bases to a mean depth of x2721307. The
sequencing resulted in 45272–11767856 reads per sample.
Ion torrent Variant caller v4.0-r73742 with no Hotspot region and configuration “Germ
Line Low Stringency” was used for calling variants. Read counts for all positions were com-
puted using pileup (SAMtools v1.1 [12]) and this data was analysed for possible variants using
custom Perl and R scripts. Variants at> 3% reported by both analysis methods and not
reported in 1000 Genomes Project database (www.1000genomes.org) were identified as possi-
ble somatic mutations. The data was cross referenced against the Cosmic database v70 (cancer.
sanger.ac.uk) to identify possible hotspot mutations.
Statistical analysis
Linear regression was performed using the formula r2 = 1-(SSreg/SStot) where SSreg refers to the
sum of the squares of distances to best-fit linear regression line and SStot refers to the sum of
the squares of vertical distances from the null hypothesis (y = mean of all y values) using
GraphPad Prism version 6.0a (GraphPad Software, La Jolla, California, USA).
KRASmultiplex assay specificity
92 wells of KRAS wild-type gDNA were analysed with each multiplex. The limit of detection
was set at 0.05% to reflect our measured results with spiked KRASmutant gDNA species (S8
Fig). Individual droplets were clustered according to their HEX amplitude into two groups
using the kMeans algorithm. A threshold for mutants was estimated based on 1.5 times the
median of the FAM values of those drops that belong to the cluster with higher HEX categories.
False positive ‘mutant’ droplets were classified as droplets that were in the lower HEX cluster,
but whose FAM value exceeds the threshold to reflect the FAM and HEX amplitudes measured
for any of the KRAS mutant species tested for in that multiplex assay. A false positive result was
defined as three false positive ‘mutant’ droplets as per the Rare Mutation Detection Best Prac-
tices Guidelines [13]. To assess the specificity, we calculated the binomial probability of achiev-
ing fewer than three ‘mutant’ droplets per 6000 wild-type droplets for each multiplex assay.
Results
KRASmutation duplex ddPCR
We tested all KRAS ddPCR assays separately across an annealing temperature gradient to opti-
mise thermocycling conditions. Each assay was tested with the appropriate gDNA or
Mutant KRAS Digital PCR for Lung Cancer Genotyping
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oligonucleotide alone and then in duplex with wild-type and KRASmutant DNA and both rel-
evant FAM and HEX probes present. Decreasing annealing temperature increased FAM ampli-
tude of the mutant probe to a plateau at 54°C for KRAS G12V, D, A, S, R and C and G13C and
13D probes (Fig 1). The KRAS Q61H probe had a further minimal increase in FAM amplitude
at 53.4°C as compared to 54°C. All probes tested showed good separation of the four different
droplet groups at 54°C, allowing clear identification and quantification of different DNA
populations.
KRASmultiplex ddPCR assay design
We designed a digital PCR-based multiplex tool to screen for the most common KRASmuta-
tions in lung adenocarcinoma; G12C, G12D and G12V (http://www.sanger.co.uk/cosmic).
Wild-type probe assays for each mutation were tested in combination with varying concentra-
tions of mutant probe assays, giving rise to mutant droplet populations of varying FAM ampli-
tude (Fig 2). The HEX amplitude of all wild-type probe assays was found to be very similar and
so the WT for G12C, WT for G12V and WT for G12D assays were selected as references for all
subsequent KRAS G12 and G13 mutant assays. Of the different combinations of mutant assays
trialled, the multiplex assay which gave best separation of the droplet populations used 900 nM
primers and 500 nM G12C probe, 562.5 nM primers and 312.5 nM G12D probe and 225 nM
primers and 125 nM G12V probe (Fig 2, top left panel).
The ability to test for multiple KRASmutations would help to detect sub-clonal populations
by applying the multiplex approach to clinical samples on which starting material is scarce. To
model this, we employed cell-line derived gDNA for the three mutations and tested it with
each probe in duplex to ensure specificity (S1 Fig). In the presence of the G12D mutant probe
and KRAS G12D, V and C mutant DNA, a second mutant population of droplets was identified
Fig 1. KRAS duplex assays at optimal annealing temperature. Droplet populations observed for each duplex assay tested with wild-type and relevant
mutant cell line gDNA or oligonucleotide at the optimal annealing temperature e.g. G12V panel top left shows droplet populations seen with WT for G12V
assay, G12V assay, NCI-H727 gDNA and NCI-H1975 gDNA present. HEX amplitude is up to 6000 on the x axis and FAM amplitude up to 11000 on the y-
axis of each panel. Key: Black drops- empty droplets, blue- mutant DNA FAM positive droplets, green- wild-type DNA HEX positive droplets, brown—wild-
type and mutant DNA double positive droplets.
doi:10.1371/journal.pone.0139074.g001
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at lower FAM amplitude to the G12D mutant DNA population (red hatched box, left upper-
most panel). This population was not observed when each mutant DNA species was tested in
duplex with the G12D probe (left second panel). A similar second mutant population was
observed with the G12V mutant probe and all three mutant DNA species as compared with
each mutant DNA in duplex (left lower panels). This second population, particularly as seen
with the G12D mutant probe, may fall at the expected FAM amplitude of a different KRAS
mutation in the multiplex assay and lead to false positive mutation detection. To further
explore this, FFPE tissue DNA from an individual known to have a KRAS 12/13 mutation
(F124), as verified by Cobas1 testing (Cobas1 KRASMutation Test, Roche Molecular Systems,
Inc., Branchburg, NJ, USA) was analysed (S1 Fig, right panels). The multiplex assay identified
a mutant droplet population with FAM amplitude that was interpreted as a G12D or G12V
mutation. When the sample was tested with each duplex assay individually, no mutant popula-
tion in either G12V or G12C was observed, whilst a population with a lower FAM amplitude
than expected with the G12D mutant assay was observed. On subsequent sequencing and fur-
ther development of the digital PCR analysis of the tissue DNA, this sample was later identified
as KRAS G12A mutant (Table 3).
Fig 2. Four different KRASmultiplex digital PCR assays combining G12C, G12V and G12Dmutant assays and corresponding duplex assays.
KRASG12Cmutant droplet populations are indicated by a red dashed square, KRASG12Dmutant populations by a blue dashed square and KRASG12V
mutant populations by a yellow dashed square. Each multiplex assay, combining all relevant FAM and HEX assays, KRASWT gDNA and G12V, D and C
mutant gDNA, is shown in the top panel. The corresponding duplex assay for each mutation, using the same FAM and HEX assay concentration with KRAS
WTDNA and the appropriate KRASmutant DNA present, is shown in the panels below each multiplex assay. Multiplex 1 (top left panel) is an assay
combination of 900 nM primers and 500 nM G12C probe, 562.5 nM primers and 312.5 nMG12D probe and 225 nM primers and 125 nMG12V probe with 450
nM primers and 250 nMWT for G12C probe. Multiplex 2 uses the same concentration of G12V andWT for G12C assay as Multiplex 1 but also contains 450
nM primers and 250 nMG12C probe and 675 nM primers and 375 nMG12D probe. Multiplex 3 uses the same concentration of KRASmutant assays as in
Multiplex 2 but with the WT for G12V probe assay present, used at the same concentration as the WT for G12C assay in Multiplex 1. Multiplex 4 is an assay
combination of the G12C assay as in Multiplex 2 with 225 nM primers and 125 nM G12D probe and 675 nM primers and 375 nM G12V probe with the WT for
G12D assay at the same concentration as theWT for G12C assay in Multiplex 1. Key: black- empty droplets, blue- mutant DNA FAM positive droplets, green-
wild-type DNA HEX positive droplets, brown—wild-type and mutant DNA double positive droplets. The same scale is used for all panels (HEX amplitude up
to 7000 and FAM amplitude up to 22000).
doi:10.1371/journal.pone.0139074.g002
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Cross-reactivity of KRAS probe assays on combination
Due to the close similarities between the DNA sequences of the various KRASmutations, sig-
nificant cross-reactivity was noted between probes designed for mutations within the same
region. This was particularly evident with probes designed for substitutions at the same nucleo-
tide i.e. KRAS G12V, D and A and KRAS G12S, R and C. The cross-reactivity of the probe
assay with ‘mismatched’DNA carrying a different KRASmutation (S2 and S3 Figs) results in a
droplet population of varying FAM and VIC amplitudes relatively close to the empty droplet
population and another population close to the true wild-type droplet population. The position
of these additional droplet populations dictates the design of multiplex assays to reduce poten-
tial misinterpretation of KRAS genotypes. Therefore, three multiplex assays were devised to
each combine a probe for a mutation at nucleotide position 35, a probe for a mutation at posi-
tion 34 and a probe for a mutation at either position 37, 38 or 183.
KRASmultiplex ddPCR assay optimisation
Multiplex A is a combination of FAM assays for KRASG13C, G12C and G12V. Several different
combinations of mutant probe concentrations were tested and the use of a wild-type probe for
G12C and G13C at varying concentrations (S4 Fig). There was significant overlap between the
HEX amplitude of the wild-type droplet populations and due to the proximity of the relevant
nucleotide bases and the estimated length of the probe, it was felt that 450 nM primers and 250
nM G12C, V or D wild-type probe was adequate for quantification of both G12 and G13 wild-
type populations. The optimal multiplex assay (S4 Fig, top left panel) comprised 900 nM prim-
ers and 500 nM G13Cmutant probe, 450 nM primers and 250 nM G12C probe and 225 nM
primers and 125 nM G12V probe. Multiplex B is a combination of FAM assays for KRAS G12S,
G12D and G13D. Of all the concentrations tested, the optimal combination of mutant probe
assays was 675 nM primers and 375 nM G12S probe, 450 nM primers and 250 nM G12D probe
and 225 nM primers and 125 nM G13D probe (S5 Fig, top left panel). Multiplex C analyses
KRASmutations at G12R, G12A and Q61H. It requires a wild-type probe for both the G12/13
position and the Q61 position for accurate quantification of mutant allele frequency. The assay
Table 3. Detection of KRASmutant clones in FFPE tissue DNA using next generation sequencing
(NGS) and KRASmultiplex digital PCR assays.
ID KRAS
genotype
NGS mutant allele frequency
(%)
Digital PCR multiplex mutant allele
frequency (%)
S007 G12C 30.4 29.5
S027 G12C 48 53.8
F007 G12D 4 4.6
S002 G12A 32 30
S010 G12C ND 0.3
G12A 8.8 8.7
S011 G12V 33.1 32.8
G12D ND 0.05
S018 G12F 29 29.5
S030 G13C 17 18.6
S035 G12C 30 19.8
F124 G12A 23 23.7
F130 G12V 28 34.2
Key: ND- not detected.
doi:10.1371/journal.pone.0139074.t003
Mutant KRAS Digital PCR for Lung Cancer Genotyping
PLOS ONE | DOI:10.1371/journal.pone.0139074 September 28, 2015 8 / 18
was optimised with 450 nM primers and 250 nM G12C probe and 900 nM primers and 500 nM
Q61H probe as the wild-type assays. The best separation of the mutant droplet populations was
achieved using 675 nM primers and 375 nM G12R probe, 450 nM primers and 250 nM G12A
probe and 900 nM primers and 500 nMQ61H mutant probe (S6 Fig, top left panel).
All optimised multiplex assays (Fig 3) were tested for cross-reactivity with various species of
KRASmutant DNA (S7 Fig). There is no overlap between the desired droplet populations and
the populations for the other KRASmutant DNA species in all three multiplexes. In addition,
the position of droplet populations due to cross-reactivity is highly reproducible and can be
used to start to identify which KRAS genotype is present in a multiplex assay containing other
mutant probes.
KRASmultiplex ddPCR assay characterisation
Decreasing amounts of NCI-H358 (KRAS G12C) and A549 (KRAS G12S) gDNA were spiked
into KRAS wild-type gDNA (NCI-H1975) and tested in the appropriate KRASmultiplex assay.
The limit of detection for KRAS G12C mutant DNA in multiplex A was 0.03% and for KRAS
G12S DNA in multiplex B was 0.045% (S8 Fig, top panels) The measured mutant allele fre-
quency correlated well with decreasing amounts of spiked KRASmutant gDNA in multiplexes
A and B (r2 = 0.9992 and 0.0998 respectively), demonstrating the linearity of mutation detec-
tion in the multiplex assays. Mutant allele frequency showed little intra-well variability for
either multiplex assay and high reproducibility between two different operators on three alter-
nate days for a range of allele frequencies (S8 Fig, middle and bottom panels).
Similar KRAS allele frequency was observed using multiplex or duplex assays in both cell
line DNA (single species KRASmutant gDNA and combinations of KRASmutant gDNA at
varying allele frequencies) or oligonucleotides and FFPE tissue DNA (Fig 4; r2 = 0.9302 and
0.9542 respectively).
We analysed multiple wells of NCI-H1975 KRAS wild-type gDNA with each of the three
KRASmultiplex assays and calculated the probability of false positive mutation detection, set-
ting the limit of detection at 0.05% to reflect our measured results with spiked KRASmutant
gDNA species (S8 Fig). The specificity of each multiplex is 99.99995%, 99.99857% and
99.85578% for multiplexes A, B and C respectively (S1 Table).
Comparison of KRASmultiplex assay mutant detection with Sanger
sequencing
A range of samples containing decreasing amounts of NCI-H358 (KRASG12C) or A549 (KRAS
G12S) gDNA spiked into KRAS wild-type DNA (NCI-H1975) were simultaneously analysed
using digital PCR and Sanger sequencing. KRASG12Cmutant DNA was detectable using multi-
plex A down to a mutant allele frequency of 0.2%, whereas the mutant peak on the chromato-
gram is only visible at a mutant allele frequency of 31.5% and not below 10% (S9 Fig, top panels).
KRASG12S mutant DNA remains detectable by digital PCR using multiplex B at a mutant allele
frequency of 0.1%, but is only visible using Sanger sequencing at 17%. (S9 Fig, lower panels).
Detection of KRASmutations in FFPE tissue DNA
FFPE tissue DNA extracted from 11 cases of advanced KRASmutant NSCLC (S2 Table) was
analysed using each multiplex assay. The presence of a KRAS 12/13 mutation was known from
prior Cobas1 testing (Cobas1 KRASMutation Test, Roche) but investigators were blinded to
the specific KRAS genotype. At least one KRASmutation was detected in each case and two
cases had two detectable KRAS clones (Fig 5). Mutations were confirmed with the appropriate
duplex assay. The low frequency G12D mutation in case S011 may represent FFPE artefact due
Mutant KRAS Digital PCR for Lung Cancer Genotyping
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to the frequent deamination of guanine nucleotides during the tissue preservation process [14].
The G12F mutation in S018 was identified by subsequent sequencing of the tissue sample after
observation of the cross-reactivity droplet population in all multiplex assays. In addition, two
species of KRAS mutant gDNA were spiked into a background of KRAS wild-type DNA
(NCI-H1975) gDNA to create three samples containing a major and minor KRAS clone; C1 is
Fig 3. KRASmultiplex digital PCR assays A-C and corresponding duplex assays.Multiplex A (top left panel) is an assay combination of 900 nM primers
and 500 nMG13C probe (red dashed square), 450 nM primers and 250 nMG12C probe (blue dashed square) and 225 nM primers and 125 nMG12V probe
(yellow dashed square). Multiplex B (top middle panel) is an assay combination of 675 nM primers and 375 nMG12S probe (red dashed square), 450 nM
primers and 250 nM G12D probe (blue dashed square) and 225 nM primers and 125 nMG13D probe (yellow dashed square). Multiplex C (top right panel) is
an assay combination of 675 nM primers and 375 nMG12R probe (red dashed square), 450 nM primers and 250 nMG12A probe (blue dashed square) and
900 nM primers and 500 nMQ61H probe (yellow dashed square). Multiplex C has 900 nM primers and 500 nM Q61H wild-type probe in addition to a G12C
wild-type assay. All other wild-type droplet populations shown, except in the Q61H duplex assay, are 450 nM primers and 250 nMG12C wild-type probe. All
panels in the left and centre columns show a FAM amplitude up to 18000 and an HEX amplitude up to 6000. Panels in the right column have a FAM
amplitude up to 18000 and a HEX amplitude up to 11000.
doi:10.1371/journal.pone.0139074.g003
Fig 4. Correlation of mutant DNA fraction detected in multiplex and duplex assays using cell line gDNA or oligonucleotides (left) and in FFPE
tissue DNA (right).
doi:10.1371/journal.pone.0139074.g004
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a combination of NCI-H358 (KRAS G12C) and A549 (KRAS G12S) gDNA, C2 is a combina-
tion of NCI-H358 (KRAS G12C) and A427 (KRAS G12D) gDNA and C3 is a combination of
A427 (KRAS G12D) and A549 (KRAS G12S) gDNA. All KRAS species were detectable using
the KRAS multiplex assays, including the minor clones down to a mutant allele frequency of
0.3% measured for the KRAS G12D mutant DNA in sample C3 (Fig 6).
Fig 5. KRASmutant FFPE tissue DNA analysis usingmultiplex and duplex assays to detectKRASmutant clones. All samples, except for S011, were
analysed with multiplexes A, B and C (upper panels) and the KRASmutation detected was subsequently confirmed with the appropriate duplex assay (lower
panels). Mutant DNA droplet populations are highlighted with a red dashed square. Droplet populations caused by cross-reactivity with a KRASmutant DNA
species not present in the multiplex are indicated by a yellow dashed square.
doi:10.1371/journal.pone.0139074.g005
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Fig 6. KRASmutant biclonal gDNA analysis usingmultiplex and duplex assays to detectKRASmutant clones. All samples were analysed with
multiplexes A, B and C (upper panels) and the KRASmutation detected was subsequently confirmed with the appropriate duplex assay (lower panels).
Mutant DNA droplet populations are highlighted with a red dashed square. Droplet populations caused by cross-reactivity with a KRASmutant DNA species
not present in the multiplex are indicated by a yellow dashed square.
doi:10.1371/journal.pone.0139074.g006
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Comparison of KRASmultiplex assay mutant detection with next
generation sequencing
FFPE tissue DNA from all 11 cases and gDNA from the 3 biclonal cell line DNA samples were
sequenced using the Ion Ampliseq Cancer Hotspot Panel v2 on the Ion ProtonTM platform
(Life Technologies) to analyse the KRAS 12 and 13 loci. Next generation sequencing could not
detect KRAS mutant allele frequencies below 4% in tissue DNA and none of the minor clones
below 2% were detectable in the biclonal gDNA samples in either of the duplicate library prep-
arations (Tables 3 and 4). The frequency of KRASmutant alleles that were detectable on next
generation sequencing correlate well with those measured in the KRAS multiplex digital PCR
assays (Fig 7, r2 = 0.8973).
Discussion
We have used commercially available primer probe assays for nine common KRASmutations
to design and optimize a multiplex assay approach to genotype KRASmutant cancers using
limited material using digital droplet PCR. The Bio-Rad QX200 system has been used to ana-
lyse copy number variation in a multiplexed fashion with EvaGreen DNA binding dye [15] but
this is the first report of KRASmutation detection multiplex assays on the QX100 system that
are based on varying concentrations of the primer probe assays.
These multiplex assays permit the identification of the specific KRAS genotype and we have
observed that this can be deduced from the reproducible droplet populations caused by cross-
reactivity in any of the multiplex assays as well as the positive mutant droplet populations at
the predicted FAM amplitude. These multiplexes can therefore be used to identify the presence
of rarer KRASmutations at the G12/13 and Q61 positions other than those already tested for
in the multiplex assays, as demonstrated with case S018.
Sub-clonal mutations can also be detected using this ddPCR approach to KRASmutation
detection. In two cases, S010 and S011, two different KRASmutations were detected both in
multiplex and duplex. We have noted, however, that all the mutations tested in multiplex B,
are G>A nucleotide changes. Low frequency single nucleotide changes as an artifact of the tis-
sue preservation process have been observed [16]. The KRAS G12D mutation observed in S011
(mutant allele frequency 0.05%) may therefore be a false positive result. The low frequency
KRAS G12C mutation in S010, however, is a G>T change and therefore much more likely to
be a true result.
We have demonstrated that the multiplex assays are more sensitive than Sanger and next
generation sequencing and highly specific. The assays have linearity down to a limit of
Table 4. Detection of KRASmutant clones in biclonal gDNA samples using next generation sequencing (NGS) andKRASmultiplex digital PCR
assays. Two individual library preparations were analysed for each sample.
ID KRAS
genotype
Library 1 NGS mutant allele frequency
(%)
Library 2 NGS mutant allele frequency
(%)
Digital PCR mutant allele frequency
(%)
C1 G12C 25 23 19.4
G12S ND ND 1.9
C2 G12C 26 26 18.4
G12D ND ND 0.49
C3 G12D 9 10 9.8
G12D ND ND 0.58
Key: ND- not detected.
doi:10.1371/journal.pone.0139074.t004
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detection of 0.03–0.045%. Due to the false positive signal seen from FFPE tissue on NGS below
mutant allele frequencies of 1.5%[17], the limit of detection is at best 1 mutant KRASmolecule
in 50 wild-type KRASmolecules. The KRAS G12S minor clone in the C1 gDNA sample that
was measured at 1.9% on multiplex digital PCR, for example, was not detectable on NGS in
either of two independent library preparations. Sanger sequencing, in comparison, has a limit
of detection of only 1 in 10 and over a range of mutant allele frequencies, a sensitivity of 20%.
Digital PCR maintains a very high specificity despite this increased sensitivity and is approach-
ing the 100% specificity seen with NGS [17]. The accuracy of KRASmultiplex ddPCR is
reflected by the correlation observed with the mutant allele frequency detected by Ion Torrent
ProtonTM sequencing, an established method of determining this variable. In addition, we have
demonstrated the robustness of the multiplex assays across a range of mutant allele frequencies
both within the same experiment and between operators on three non-consecutive days.
We have described the combination and optimization of commercially available digital PCR
assays to develop novel multiplex assays that allow the accurate detection and discrimination
of KRAS genotypes in patient-derived material. Multiplexing of assays reduces the amount of
clinical material required for testing, which will be particularly important in settings where the
proportion of mutant relative to wild-type DNA is likely to be low, such as with circulating free
tumour DNA from plasma samples. The three multiplexed assays described here between
them will identify the nucleotide changes in 95% of the cancer cases where the KRAS gene is
mutated.
Supporting Information
S1 Fig. Specificity of KRASmultiplex assay in presence of various mutant KRASDNA spe-
cies. Left panels: KRAS G12V, G12C and G12D mutant DNA tested with 562.5 nM primers
and 312.5 nM G12D FAM probe in one well (top left panel) or in three separate wells (i.e. one
well G12V DNA with G12D probe assay etc.). Wells with only one type of KRASmutant DNA
are merged (left second panel) to compare with the single well containing all DNA species.
KRAS G12V, G12C and G12D mutant DNA tested with 225 nM primers and 125 nM G12V
FAM probe in one well (left third panel) or in three separate wells (wells merged, left bottom
Fig 7. Correlation of NGS KRASmutant allele frequency with digital PCRKRASmutant allele
frequency detected in the appropriate multiplex assay for FFPE tissue DNA and cell line gDNA
samples.
doi:10.1371/journal.pone.0139074.g007
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panel). A second droplet population with lower FAM amplitude is detected when more than
one species of KRASmutant DNA is present (red dashed box). Right panels: KRAS 12/13 FFPE
tissue DNA sample (F124) tested with multiplex assay (top right) and then 3 separate duplex
assays as indicated. The same scale is used for all panels (HEX amplitude up to 7000 and FAM
amplitude up to 11000).
(EPS)
S2 Fig. Cross-reactivity of KRASmutant probes with KRASmutation variants. Duplex
assays for different KRASmutations (horizontal) with different KRASmutation variants (verti-
cal). More cross-reactivity, indicated by a droplet population near the empty droplets with rela-
tively low FAM and HEX amplitude and a population near the true wild-type population
(examples in red dashed square in top right panel), was seen between probes and DNA for the
same nucleotide position in exon 2 of KRAS. Each panel shows FAM amplitude of up to 10000
and HEX amplitude between 1000 and 6000.
(EPS)
S3 Fig. Cross-reactivity of KRASmutant probes with KRASmutation variants (greater
magnification).Duplex assays for different KRASmutations (horizontal) with different KRAS
mutation variants (vertical). More cross-reactivity, indicated by a droplet population near the
empty droplets with relatively low FAM and HEX amplitude and a population near the true
wild-type population (examples in red dashed square in top right panel), was seen between
probes and DNA for the same nucleotide position in exon 2 of KRAS. Key: X—omitted panel
of duplex assay with correct probe and KRASmutation variant as higher magnification. Each
panel shows FAM amplitude of up to 3000 and HEX amplitude between 1000 and 6000.
(EPS)
S4 Fig. KRASmultiplex digital PCR assays combining G12C, G12V and G13C and corre-
sponding duplex assays. G13C populations are indicated by a red dashed square, G12C popu-
lations by a blue dashed square and G12V droplet populations are indicated by a yellow dashed
square. Multiplex 1 (top left panel) is an assay combination of 900 nM primers and 500 nM
G13C probe, 450 nM primers and 250 nM G12C probe and 225 nM primers and 125 nM G12V
probe, with 900 nM primers and 500 nMWT for G12C probe and 450 nM primers and 250 nM
WT for G13C probe. Multiplex 2 (centre left) uses the same FAM assay concentrations as in
Multiplex 1 with 450 nM primers and 250 nMWT for G12C probe and 900 nM primers and
500 nMWT for G13C probe. Multiplex 3 (centre right) is a combination of 450 nM primers
and 250 nM G13C probe and 900 nM primers and 500 nM G12C probe with the same G12V
andWT G12C and G13C assays as in Multiplex 1. Multiple 4 uses the same FAM assays con-
centrations as Multiplex 3 with theWT for G12C and G13C assay concentrations as in Multi-
plex 2. Each panel shows a FAM amplitude up to 18000 and a HEX amplitude up to 12000.
(EPS)
S5 Fig. KRASmultiplex digital PCR assays combining G12S, G12D and G13D and corre-
sponding duplex assays. G12S droplet populations are indicated by a red dashed square,
G12D populations by a blue dashed square, and G13D populations by a yellow dashed square.
Multiplex 1 (top left panel) is an assay combination of 675 nM primers and 375 nM G12S
probe, 450 nM primers and 250 nM G12D probe and 225 nM primers and 125 nM G13D
probe with 225 nM primers and 125 nMWT for G12C probe and 450 nM primers and 250 nM
WT for G13D probe. Multiplex 2 (top middle panel) is a FAM assay combination of 225 nM
primers and 125 nM G12S probe, 675 nM primers and 375 nM G12D probe and 450 nM prim-
ers and 250 nM G13D probe with the sameWT for G12C and G13D assay concentrations as in
Multiplex 1. Multiplex 3 (top right panel) is a combination of, 450 nM primers and 250 nM
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G12S probe, 675 nM primers and 375 nM G12D probe and the same FAM 13D assay concen-
tration as in Multiplex 1. WT assay concentrations are 450 nM primers and 250 nMWT for
G12C probe and 225 nM primers and 125 nMWT for G13D probe. Each panel shows a FAM
amplitude up to 18000 and a HEX amplitude up to 9000.
(EPS)
S6 Fig. KRASmultiplex digital PCR assays combining G12R, G12A and Q61H and corre-
sponding duplex assays. G12R droplet populations are indicated by a red dashed square, G12A
populations by a blue dashed square and Q61H populations by a yellow dashed square. Multi-
plex 1 (top left panel) is an assay combination of 675 nM primers and 375 nMG12R probe, 450
nM primers and 250 nMG12A probe and 900 nM primers and 500 nMQ61H probe with 450
nM primers and 250 nMWT for G12C probe and 900 nM primers and 500 nMWT for Q61H
probe. Multiplexes 2–4 use the sameWT assay concentrations. Multiplex 2 (centre left panel) is
a FAM assay combination of 450 nM primers and 250 nMG12R probe and 675 nM primers and
375 nMG12A probe with the same FAMQ61H assay concentration as in Multiplex 1. Multiplex
3 (centre right panel) is an assay combination of 900 nM primers and 500 nMG12R probe, 225
nM primers and 125 nMG12A probe and 450 nM primers and 250 nMQ61H probe. Multiplex
4 (top right panel) is an assay combination of 450 nM primers and 250 nMG12A probe and 225
nM primers and 125 nMQ61H probe with the same FAMG12R assay as in Multiplex 3. Each
panel shows a FAM amplitude up to 16000 and a HEX amplitude up to 11000.
(EPS)
S7 Fig. Cross-reactivity of KRASmultiplex assays with KRASmutation variants. Droplet
populations seen with the addition of cell line DNA or oligonucleotides containing different
KRASmutation variants and analysed with multiplexes A, B and C. Multiplex A is an assay
combination of G13C, G12C and G12V. Multiplex B is an assay combination of G12S, G12D
and G13D. Multiplex C is an assay combination of G12R, G12A and Q61H. Panel A1 –multi-
plex A with KRAS G12V, C, D, S and R DNA; panel A2 –multiplex A with KRAS G12A DNA;
panel A3- multiplex A with KRAS G13C and G13D DNA. Panel B1 –multiplex B with KRAS
G12V, C, D, S and R DNA; panel B2 –multiplex B with KRAS G12A DNA; panel B3- multiplex
B with KRAS G13C and G13D DNA. Panel C—multiplex C with KRAS G12V, C, D, S, R, A,
13C, 13D and Q61H DNA. Panels A1-3 and B1-3 show a FAM amplitude up to 18000 and an
HEX amplitude up to 7000. Panel C has a FAM amplitude up to 18000 and a HEX amplitude
up to 10000. Key:  = KRAS G12V mutant DNA, ¶ = G12D, ⌃ = G12C,$ = G12S, ♦ = G12R, •
= G12A, § = G13C,& = G13D; black- empty droplets, blue- mutant DNA FAM positive drop-
lets, green- wild-type DNA HEX positive droplets, brown—wild-type and mutant DNA double
positive droplets.
(EPS)
S8 Fig. KRAS multiplex assay performance. Left panels: Multiplex A tested with decreasing
amounts of KRASmutant G12C DNA spiked in against a KRAS wild-type DNA background;
right panels: Multiplex B tested with decreasing amounts of KRASmutant G12S DNA against
a KRAS wild-type DNA background. Top panels: Correlation of amount of input KRASmutant
DNA with measured mutant allele frequency. Middle panels: Mutant allele frequency per well
as compared with mean mutant allele frequency across all wells for a range of allele frequencies
(0.05–4% multiplex A and KRAS G12C, 0.08–3% multiplex B and KRAS G12S). Bottom panels:
Mutant allele frequency measured on three non-adjacent days by two different operators across
a range of amounts of spiked KRASmutant DNA. Key: Triangle = Day 1, square = Day 2,
circle = Day 3.
(EPS)
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S9 Fig. Comparison of KRASmutant DNA detection in KRASmultiplex assays A and B
compared with Sanger sequencing of gDNA samples. KRAS G12C mutant DNA samples at
allele frequencies ranging from 0.2–31.5% analysed by digital PCR in KRASmultiplex assay A
(upper panels) or Sanger sequencing (upper chromatograms). KRAS G12S mutant DNA sam-
ples at allele frequencies ranging from 0.1–17% analysed by digital PCR in KRASmultiplex
assay B (lower panels) or Sanger sequencing (lower chromatograms). All panels in the upper
row show a FAM amplitude up to 10000 and a HEX amplitude up to 6000. Panels in the lower
row have a FAM amplitude up to 14000 and a HEX amplitude up to 11000. Key: black- empty
droplets, blue- mutant DNA FAM positive droplets, green- wild-type DNAHEX positive drop-
lets, brown—wild-type and mutant DNA double positive droplets; black arrow—mutant nucle-
otide not discernible from background signal on Sanger sequencing, red arrow—mutant
thymine nucleotide detectable using Sanger sequencing, green arrow—mutant adenine nucleo-
tide detectable using Sanger sequencing.
(EPS)
S1 Table. KRASmultiplex assay specificity.
(DOC)
S2 Table. Clinical characteristics of 11 patients with lung adenocarcinoma included in the
FFPE tissue analysis. Key: F- former smoker, S- smoker, N- never smoker, Unk- unknown.
(DOC)
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